New BÜHLMANN fCAL® ELISA Citation: The team around James Turvill has proposed a highly useful care pathway for monitoring Crohn’s Disease patients. The care pathway offers a very high positive predictive value for the detection of patients with potential flare-ups of their disease while safely identifying those patients in which the therapy could be stepped down. Turvill J, Rook L, Rawle
- info@buhlmannlabs.ch
- +41 61 487 12 12
Blog Archives
BÜHLMANN improved the efficiency of the application by reducing the pipetting volumes to a minimum and applying a different dispense mode within the application. The performance of the assay has been confirmed and no changes in the specifications were found. Today, BÜHLMANN offers this new application with an improved cost/performance ratio. The new application note
BÜHLMANN will be present with a Booth at ECCO. Don’t miss the chance to get an update on our divers calprotectin product portfolio
Roche Diagnostics Switzerland recently announced the successful collaboration with BÜHLMANN Laboratories AG in bringin the BÜHLMANN fCAL® turbo Calprotectin assay onto their cobas® platform. On the Roche cobas® modular platform the BÜHLMANN fCAL® turbo calprotectin assay can be easily installed and run. In several laboratories on the cobas® c501 modules the assay has been already installed
Social Links